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Introduction: Obesity becomes endemic today. Monosodium glutamate was proved as obesogenic food additive.
Probiotics are discussed to impact on obesity development.
Aims and objectives: The aim was to study the effects of probiotics on the development of monosodium
glutamate (MSG)-induced obesity in rats.
Material and methods: We included 45 Wistar male rats and divided into three groups (n = 15). Newborn rats of
group 1 (control) received subcutaneously 8 μl/g saline. Group 2 received 3 to 4 mg/g MSG subcutaneously on the
second, fourth, sixth, eighth and tenth day of life. Within 4 months after birth, rats were on a standard diet. Group 3
received an aqueous solution of probiotics mixture (2:1:1 Lactobacillus casei IMVB-7280, Bifidobacterium animalis VKL,
B. animalis VKB) at the dose of 5 × 109 CFU/kg (50 mg/kg) intragastrically. Administration of probiotics was started
at the age of 4 weeks just after weaning and continued for 3 months during 2-week courses. Group 2 received
intragastrically 2.5 ml/kg water. Organometric and biochemical parameters in all groups of rats were analyzed over
4 months. The concentration of adiponectin was determined in serum, and leptin - in adipose tissue.
Results: Administration of MSG led to the development of obesity in rats; body weight had increased by 7.9% vs
controls (p < 0.05); body length had increased by 5.4% (p < 0.05). Body mass index and Lee index and visceral fat
mass had increased (p < 0.001). Under the neonatal injection of MSG, the concentration of total cholesterol,
triglycerides, VLDL cholesterol and LDL cholesterol significantly increased (p < 0.001), in comparison with controls.
Adipose-derived hormones changed in MSG obesity rats: adiponectin decreased by 58.8% (p < 0.01), and leptin
concentration in adipose tissue had increased by 74.7% (p < 0.01). The probiotic therapy of rats from group 3 prevented
obesity development. Parameters of rats treated with probiotic mixture did not differ from that in the control.
Conclusions: The introduction of MSG to newborn rats caused the obesity in adulthood. Periodic administration of
probiotic mixture to rat injected with MSG neonatally resulted in recovery of lipid metabolism and prevention of the
obesity development.
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Predictive, preventive and personalized anti-obesity concerns
Metabolism is an essential process for the maintenance
of life and homeostasis of the organism. Diseases associ-
ated with metabolic disorders such as hyperlipidemia,
diabetes and obesity have become extremely common
[1,2]. Today, obesity becomes endemic; about 1.7 bil-
lion people on the planet are overweight. World Health
Organization (WHO) has declared obesity a global epi-
demic and took it under control [1]. Overweight and
obesity cause the leading severe diseases, namely, dia-
betes mellitus type 2, cardiovascular diseases (CVD)
and breast cancer [3]. The permanently growing cohort
of patients with obesity-related diseases, as diabetes,
requires the urgent change paradigm from interven-
tional measures to predictive, preventive and personal-
ized medicine (PPPM) [4,5].
Metabolic disturbances in obesity causes a number
of diseases, namely, cardiovascular diseases (hypertension,
atherosclerosis, coronary heart disease), stroke, insulin-
dependent diabetes, premature death, diseases of musculo-
skeletal system (osteochondrosis and metabolic-dystrophic
arthritis), hepatobiliary disease (gallbladder dyskinesia,
chronic cholecystitis, cholelithiasis) and number of
tumor sites, including lung cancer, breast cancer, uter-
ine cancer and ovarian; in women, there is a violation of
ovarian-menstrual cycle dyslipidemia. Obesity reduces
life expectancy by 3 to 5 and, sometimes, in severe forms,
for 15 years [6,7].
Health and disease of individuals and of populations
are the result of three groups of factors: genetics, en-
vironment and behavior. Only the latter is mostly
dependent by the choices of the single person, but as-
sessment, interventions and tailored changes are pos-
sible [8]. Many of the researchers attribute this to a
violation of the diet. The nature of nutrition today is a
serious concern; a growing consumption of ‘fast food’,
accompanied by a decrease in the proportion of the
daily diet of vegetables, fruits, milk and dairy products
seriously affects the health. The application of food
supplement for metabolic syndrome was considered
for PPPM in [9].
The recent data, regarding women’s differential responses
to lifestyle changes, support another branch of research
with a gender nutrition emphasis within predictive, pre-
ventive and personalized medicine [10].
Over the past 10 years, morbidity diseases of the gastro-
intestinal tract in children and adults have increased. In
2011, in Ukraine, 7,089,010 patients were diagnosed with
gastroenterological diseases, per 100,000 of the adult
population, 18956.3. At the end of 2011, the records
were 5,028,034 patients with diseases of the digestive
organs, i.e. 70.9% of the total registered. In 2006, there
was an increased prevalence of 11.2% [11].Monosodium glutamate
Monosodium glutamate (MSG, C5H8NO4Na, E 621) is
widely distributed and is naturally occurring in various
foods (bouillon cubes, meat tenderizers, canned food,
frozen food, potato and snack chips, barbecue sauce,
salad dressing, soups, fast food, etc.) [12].
Obesogenic properties of monosodium glutamate were
studied for decades [13,14]. Hirata et al. demonstrated that
MSG obese rats develop insulin resistance to peripheral
glucose uptake [15]. MSG induces hyperinsulinemia
in 3-month-old rats; the obesity of MSG animals is a
metabolic alteration characterized by an enhanced adipo-
cyte capacity to transport glucose and to synthetize lipids
resulting in increased insulin sensitivity [16]. It was sup-
posed that the central lesions produced by MSG treatment
disrupt the regulation of the hypothalamic-pituitary-adrenal
axis as the hyperfunctional state of adrenals revealed signs
of MSG-treated rats [17].
In Ukraine, monosodium glutamate became a legal food
additive (flavour boosters) only in 2000 after the Resolution
of Cabinet of Ministers of Ukraine no. 342 on February 17,
2000 ‘Amendments to the list of food additives authorized
for use in foodstuffs’ [18], which authorized the list of food
additives in Ukraine.
Now, it is hard to find industrially produced canned or
semi-finished products that do not include MSG. Thus,
the permissible limits may be significantly exceeded,
which can lead to diseases of the digestive tract.
Probiotics
Therefore, the search of new non-toxic means of the
obesity prevention is the urgent challenge of modern sci-
ence. Today, the question of the probiotics influence on
lipid metabolism and obesity is actively debated in the
scientific literature [19-21]. Backhed et al. were the pio-
neers in the study of the role of colon microflora in the
metabolism regulation [22]. Their findings were the
impetus for the research in this field. Further studies have
shown the alteration of intestinal microbiota composition
in overweight people. Thus, intestine microbiocenosis can
be considered the environmental factor that modulates
the development of obesity.
It was demonstrated that prolonged exposure to a high
fat diet significantly changed the composition of the
colon microflora in mice having reduced the level of
Bifidobacterium and Lactobacillus that are known to
produce many positive physiological effects, e.g. improving
the barrier function of the intestinal mucosa and having
increased levels of Firmicutes and Proteobacteria, which
produce a lot of toxic substances [23,24].
It was found that the oligofructose prebiotic which is a
supplement to a high fat diet resulted in the recovery of
the normal composition of bifidoflora, hence elimination
endotoxemia and reduction of the obesity development.
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permeability and the level of circulating endotoxin. In
addition, the growth of bifidobacteria improved the sensi-
tivity to glucose and decreased the body weight gain and
production of pro-inflammatory mediators [25-27].
Recently, the beneficial effects of probiotic bacteria on
the obesity development was established. For example,
the use of Lactobacillus gasseri SBT2055 and Lactobacillus
paracasei SSP paracasei F19 prevented the development
of diet-induced obesity [27,28]. The most important cause
of obesity is the excessive consumption of fat and easily
digestible carbohydrates, but due to accumulated data, sci-
entists believe that the uncontrolled use of food additives
such as MSG taste enhancer can also lead to obesity [29].
The aim was to investigate the effect of probiotics on
the development of experimental obesity in rats induced
by monosodium glutamate.
Methods
We included 45 Wistar male rats and divided to three
groups of 15 animals each. Newborn rats of group 1
(control) were injected with saline with a volume of
8 μl/g subcutaneously on the second, fourth, sixth,
eighth and tenth day of life. Newborn rats of groups 2
and 3 were administered with MSG dissolved in saline
at the dose 4 mg/g of body weight with a volume of
8 μl/g subcutaneously on the second, fourth, sixth, eighth
and tenth day of life [30].
Within 4 months after birth, rats were on a standard
diet. Group 3 received an aqueous solution of a mixture
of probiotics (2:1:1 Lactobacillus casei IMVB-7280,
Bifidobacterium animalis VKL, B. animalis VKB) at a
dose of 5 × 109 CFU/kg (50 mg/kg) intragastrically (i.g.).
Group 2 received water with a volume of 2.5 ml/kg i.g.,
respectively.
Group 2 respectively received 2.5 ml/kg of water
(intragastrically). Administration of probiotics was started
at the age of 4 weeks just after weaning and continued
for 3 months, intermittently alternating 2-week course of
introduction with 2-week course of break. The changes in
body weight in all groups of rats were analyzed for 4
months from birth. Four-month-aged animals were
sacrificed. The rats’ blood was collected in tubes, and
visceral adipose tissue was removed and weighed. Body
length was measured; body mass index (BMI) (the ratio
of body weight (g) of rats to the square of the body
length (cm2)) and Lee obesity index (the ratio of 1/4 of
cube root of body weight (g) to body nose-to-anus length
(cm)) were calculated.
Blood samples were kept at a temperature of 38°C for
at least 30 min and centrifuged for 10 min at 1,000 × g,
followed by collecting of serum. The concentration of
adiponectin was determined in serum, and leptin was
measured in adipose tissue by enzyme immunoassay.Adipose tissue was homogenized in the TEC buffer
(10 mM TRIS, 1 mM EDTA, 250 mM saccharose, protease
inhibitors (2.5 μg/ml leupeptin, 3.5 μg/ml aprotinin,
1 mM phenylmethanesulfonyl fluoride), 1% triton X-100)
at the rate of 4 ml buffer per 1 g of tissue. Homogenate
was centrifuged for 15 min, and then medium layer
(soluble fraction) was harvested. Cholesterol, triglycerides,
high-density lipoproteins (HDL cholesterol), low-density
lipoproteins (LDL cholesterol), very low-density lipopro-
teins (VLDL cholesterol), bilirubin, activity of alanine and
aspartate aminotransferase in serum were determined
by standard biochemical methods. All investigated param-
eters of all rats were estimated in the same material which
is serum, except leptin which was measured in visceral
adipose tissue. The concentration of leptin and adiponectin
was measured with immunoassay method using ‘BioVendor’
commercial kits (Czech Republic) (Leptin Mouse/Rat Elisa,
Adiponectin HMWMouse/Rat ELISA).
Research was conducted in compliance with the
standards of the Convention on Bioethics of the Council
of Europe’s ‘Europe Convention for the Protection of
Vertebrate Animals’ used for experimental and other
scientific purposes’ (1997), the general ethical principles
of animal experiments, approved by the First National
Congress on Bioethics Ukraine (September 2001) and
other international agreements and national legislation
in this field. Animals were kept in a vivarium that was
accredited in accordance with the ‘standard rules on
ordering, equipment and maintenance of experimental
biological clinics (vivarium)’. Instruments to be used
for research are subject to metrological control.
Statistical analysis of data was carried out by the software
package ‘Statistica 8.0’. For the analysis of data distribution
type, Shapiro-Wilks criterion was used. As the data
were normally distributed, we used Levan criterion for
evaluating the equality of variance and Student’s t test
for independent samples. We calculated mean values
(M) and standard deviations (SD). Significant difference
was considered at p ≤ 0.05.
Results
Administration of MSG in the neonatal period leads to
the development of obesity in 4-month-old rats. Table 1
shows the organopometric parameters in three groups
of rats. It was found that after 4 months in animals
injected with MSG, body weight was significantly higher
in comparison with control animals by 7.9% (p < 0.05).
This decreased the body length in the group of rats with
experimental obesity by 5.4% (p < 0.05). Body length in
group 2 was decreased by MSG introduction by 5.4%
(p < 0.05) compared to that of the control. The calculation
of body mass index and Lee index suggested the devel-
opment of obesity in group 2. The significant increase
of visceral adipose tissue mass was also observed in animals
Table 1 Organopometric parameters of glutamate-induced obesity rats and corrected parameters by probiotics
Intact rats (n = 15) MSG-induced obesity р1 р2 р3
Placebo (n = 15) Probiotic blends (n = 15)
Weight, g 241.9 ± 25.5 261 ± 17.8 256.7 ± 27.7 0.016 >0.05 >0.05
Body length, cm 21.4 ± 0.9 20.3 ± 1.6 21.5 ± 0.6 0.023 >0.05 0.011
Body mass index 0.53 ± 0.05 0.64 ± 0.08 0.56 ± 0.07 0.002 >0.05 >0.05
Lee index 0.29 ± 0.01 0.32 ± 0.02 0.30 ± 0.01 0.013 >0.05 >0.05
Visceral fat mass, g 2.53 ± 0.78 17.31 ± 5.69 10.65 ± 3.89 <0.001 <0.001 <0.001
Data are presented as the M ± SD. p1, group 1 vs group 2; p2, group 1 vs group 3; p3, group 2 vs group 3. Significant p value < 0.05.
Savcheniuk et al. The EPMA Journal 2014, 5:2 Page 4 of 17
http://www.epmajournal.com/content/5/1/2injected with MSG by 583% (p < 0.001) in comparison with
that of the control. These data confirm the findings that the
introduction of glutamate sodium to newborn rodents in-
duces the development of visceral obesity in adult animals
and is a model of obesity in rodents [30].
While the development of MSG-induced obesity was
registered, there were no functional changes in the liver.
It was confirmed by determination of bilirubin and albu-
min concentration and activity of alanine and aspartate
aminotransferase in blood serum (Table 2). However, in
the blood of animals, injected with MSG, the lipid me-
tabolism changes that are characteristic of the metabolic
syndrome are observed. Under the neonatal injection
of MSG, the concentration of total cholesterol, triglyc-
erides, VLDL cholesterol and LDL cholesterol significantly
increased by 55% (p < 0.001), 210% (p < 0.001), 210%
(p < 0.001) and 83% (p < 0.001), respectively, compared
to those of the controls (Table 3). Also, it was found that
MSG introduction influenced HDL cholesterol concentra-
tion; it decreased by 33.1% (p < 0.001).
Taking into account the literature data that adipose
tissue is an active secretory organ and can model the
development of obesity, we have investigated the con-
tents of adipose-derived hormones in rats of all groups.
Analysis of the secretory function of adipose tissue showed
a change in the concentration of adipose-derived hor-
mones in rats with experimental obesity caused by
MSG. Thus, the level of adiponectin in the serum of rats
with monosodium glutamate-induced obesity decreased
by 2.43 times (p < 0.01).
These results are confirmed by the literature data,
which shows the low levels of adiponectin in humansTable 2 Biochemical indicators of liver in blood serum of glut
Intact rats (n = 15)
Placebo (n
Alanine aminotransferase, μkat/L 0.228 ± 0.033 0.211 ± 0.031
Aspartate transaminase, μkat/L 0.389 ± 0.034 0.377 ± 0.041
Total albumin, μmol/L 12.4 ± 2.09 12.7 ± 1.53
Indirect bilirubin, μmol/L 7.9 ± 1.7 8.1 ± 1.06
Direct bilirubin, mmol/L 4.4 ± 0.91 4.6 ± 0.91
Data are presented as the M ± SD. p1, group 1 vs group 2; p2, group 1 vs group 3; pwith obesity and insulin resistance. A study on rhesus
monkeys, which simulated obesity and type 2 diabetes,
confirmed this statement and showed that adiponectin
levels decreased in parallel with the progression of data
pathological conditions [31,32]. Scherer Lab set a line of
transgenic mice with a threefold increase in adiponectin
levels in serum [33]. For this model, hyperadiponectinemia
characteristically increased the sensitivity of peripheral
tissues to insulin by improving carbohydrate and lipid
metabolism associated with increased activation of AMPK
in the liver and the expression of peroxisome proliferator-
activated receptor-gamma (PPARγ) in visceral adipose
tissue. These animals are resistant to the development of
insulin resistance induced by intake of a high fat diet [34].
Treatment of animals with recombinant adiponectin
with obesity leads to decreased hyperglycemia and free
fatty acids (FFA) in plasma and improves insulin sensitivity
[35]. Activation of PPARγ in vivo leads to increased adipo-
nectin levels [36]. In mice without adiponectin, hepatic
insulin resistance was observed in parallel with a decrease
in therapeutic response to agonists of PPARγ, indicating
that adiponectin is an important factor enhancing PPARγ-
mediated improvement in insulin sensitivity [37].
The physiological function of leptin is to prevent obesity
in excessive flow of food into the body. Reduced leptin se-
cretion during fasting is a kind of signal to increase energy
absorption. When there is excessive consumption of food,
there will be increased activation of thermogenesis energy
for the formation of brown fat by inducing the expression
of genes responsible for the synthesis of mitochondrial
proteins of type 1, 2 and 3; severe oxidative phosphoryl-
ation occurs, regulating the rate of thermogenesis in theamate-induced obesity rats and corrected by probiotics
MSG-induced obesity р1 р2 р3
= 15) Probiotic blends (n = 15)
0.221 ± 0.034 >0.05 >0.05 >0.05
0.392 ± 0.044 >0.05 >0.05 >0.05
12.3 ± 1.98 >0.05 >0.05 >0.05
7.7 ± 1.4 >0.05 >0.05 >0.05
4.6 ± 0.97 >0.05 >0.05 >0.05
3, group 2 vs group 3. Significant p value < 0.05.
Table 3 Biochemical parameters of lipid metabolism in serum of glutamate-induced obesity rats and corrected
by probiotics
Intact rats (n = 15) MSG-induced obesity р1 р2 р3
Placebo (n = 15) Probiotic blends (n = 15)
Triglycerides, mmol/L 1.15 ± 0.27 3.53 ± 0.57 2.91 ± 0.72 <0.001 <0.05 >0.05
Total cholesterol, mmol/L 4.53 ± 0.34 7.04 ± 0.26 4.72 ± 0.37 <0.001 >005 <0.001
Very low-density lipoproteins, mmol/L 0.51 ± 0.12 1.58 ± 0.26 1.07 ± 0.41 <0.001 <0.05 <0.05
HDL cholesterol, mmol/L 1.63 ± 0.14 1.09 ± 0.19 1.37 ± 0.11 <0.001 <0.05 <0.05
LDL cholesterol, mmol/L 2.37 ± 0.22 4.35 ± 0.29 3.02 ± 0.49 <0.001 <0.05 <0.05
Data are presented as the M ± SD. p1, group 1 vs group 2; p2, group 1 vs group 3; p3, group 2 vs group 3. Significant p value < 0.05.
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tissue in rats that were administered in the neonatal mono-
sodium glutamate showed an increase in this indicator by
74.7% (p < 0.01) compared to that of the intact animals
(Figure 1). With obesity, serum leptin resistance increases
due to the central hypothalamic action and lipocytokine
mechanisms for negative feedback or defect transport
through the blood–brain barrier. However, the effect of
leptin on peripheral tissues preserved, so we can suspect
the presence of selective leptin resistance. Tissues to leptin
resistance develop gradually, activating the growth of adi-
pose tissue [38]. It has been shown that the introduction
of MSG causes lesions in the arches and ventromedial
nuclei of the hypothalamus, causing insensitivity to leptin
and insulin in this region resulting in developing hyperlep-
tinemia and hyperinsulinemia [39].
Probiotic therapy performed to animals that received
MSG (4 mg/g) at 2, 4, 6, 8 and 10 days of life prevented
the development of obesity in rats. Thus, in rats injected
with probiotic mixture, there is increased body length
by 6.1% (p < 0.05) compared to that of the placebo and
not different from that of the intact controls. Proof ofFigure 1 Concentration of adipose-derived hormones. (A) Concentratio
adipose tissue of rats with glutamate-induced obesity and corrected by pro
double number signs (##), p < 0.01 in comparison with group 2.reducing obesity index was significantly reduced Lee
index and visceral fat mass.
Probiotic consumption also increased the adiponectin
level, decreased the leptin concentration in adipose tissue
and restored the anthropometric parameters and lipid
metabolism (Tables 1 and 3; Figure 1). Such results are
consistent with other studies and show effectiveness of
probiotics in obesity prevention.
Periodic administration of probiotics led to restoration
of lipid metabolism in rats. The probiotic strains have
influenced the cholesterol concentration, which has been
restored to the level of control. In organism of animals,
injected with probiotic strains, the VLDL cholesterol
concentration decreased by 32.3% (p < 0.05), LDL choles-
terol by 30.6% (p < 0.05) and HDL cholesterol increased
by 25.7% (p < 0.05) compared with those of the group 2.
These values did not reach the level of control (Table 2).
Probiotics introduction led to the normal hormonal activity
of adipose tissue.
Thus, intermittent administration of probiotics, namely
for 2 weeks, resulted in increased adiponectin levels,
decreased leptin concentrations in adipose tissue andn of adiponectin in serum (mkg/ml) and (B) concentration of leptin in
biotics; double asterisks (**), p < 0.01 in comparison with group 1;
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ism in animals that were injected with monosodium
glutamate as neonates. The results show the effectiveness
of probiotic therapy to prevent obesity, consistent with
other studies.
Study limitation
The survey was conducted on animals. We administered
MSG subcutaneously (8 ml/g); however, considering
that MSG is a food additive, the per os administration
(with mother milk for newborn animals) would be most
preferable for the relevant modeling. The study did
not consider an immunology, genetic, cellular regulation
mechanisms, obesity-related conditions, namely diabetes,
gout, autoimmunity, and many factors of obesogenic
environment and other issues that may impact to obesity
development. Research itself did not suppose the predict-
ive and personalized approaches.
Discussion
As the current research did not touch regulation mecha-
nisms of obesity and related conditions, namely diabetes,
gout, autoimmunity and many factors of obesogenic en-
vironment and other issues that impact to obesity devel-
opment, we consider to overview the series of important
obesity-associated topics, the impact of probiotics to the
obesogenic environment to crystallize the predictive and
personalized approaches in the field. Many mechanisms
of obesity are still unclear; new pathways are still awaited
and insufficiently studied and should be extensively ana-
lyzed in conjoint paradigm. We hope that the discussion
of the following issues for deeper understanding of cer-
tain mechanisms of obesity for effective translation re-
sults into real PPPM practice.
Intestinal microbiota and obesity
The gut microbiota can be considered an extension of the
self and, together with the genetic makeup, determines the
physiology of an organism, metabolism and obesity [40].
Strachan [41] described the hygiene hypothesis that refers to
an originally associated reduced microbial contact to mi-
crobes in early life and is suggested to be one of the main
mechanisms to account for the increasing prevalence of
allergic diseases over the past few decades. Today, reduced
microbial exposures (and the rise in allergic conditions)
have been attributed to Western lifestyle factors such as
diet, antibiotic use, vaccinations, reduced household size
and improved hygiene [42]. Recently, probiotic bacteria
have been tested for their ability to affect obesity.
Previously, it was shown that the decrease of the choles-
terol concentration in mice with high fat diet caused
hypercholesterolemia under the influence of Lactobacillus
та Bifidobacterium, especially L. acidophilus ІМВ В-7279,
B. animalis VKB and B. animalis VKL [43].The probiotic Lactobacillus gasseri SBT2055 was able
to reduce adiposity and body weight in obese adults con-
suming a fermented milk with the bacterium for 12 weeks,
potentially by reducing lipid absorption and inflammatory
status [44]. A study by Luoto et al. [45] showed the effect
of perinatal Lactobacillus rhamnosus GG on childhood
growth patterns; the probiotic modulated the body weight
increase in the early life but had no effect in later stages
of development.
A recent study demonstrated that Lactobacillus paracasei
ssp paracasei F19 prevented diet-induced obesity in mice
[46]. Lactoferrin (LF), a multifunctional glycoprotein in
mammalian milk, is reported to exert a modulatory effect
on lipid metabolism and improve visceral fat-type obesity,
an underlying cause of the metabolic syndrome. Using a
double-blind, placebo-controlled design, a study involved
Japanese men and women (n = 26; aged 22 to 60 years)
with abdominal obesity [47]. From these results, eLF
appears to be a promising agent for the control of
visceral fat accumulation with no adverse effects with
regard to blood lipid or biochemical parameters.
Therefore, influence of probiotics on obesity is actively
debated, and we were the first who showed the prevent-
ive influence of the probiotic treatment in rat model
with MSG-induced obesity.
However, the use of probiotics has several drawbacks;
namely, introduction of foreign microorganisms induce
antagonistic activity against pathogenic and indigenous
microorganisms, and eliminating fast the probiotic strain.
Therefore, to achieve the personalized approach, the
development and application products manufactured
from own strains of organism seem promising. For this
reason, certain individual microorganisms might be grown
on artificial nutrient, exploring their environment friendli-
ness, establish spectrum antagonistic effects on the body.
The potential alternative for probiotics might be the sug-
gested lysates of probiotic strains that also exhibit immu-
nomodulatory activity.
Obesity genetics: monogenetic vs polygenetic concept
For over a decade, obesity genetics has been predominantly
driven by research into monogenic or syndromic obesity.
Obesity tends to cluster within families and is more
closely correlated between mono- and dizygotic twins.
Studies of twins suggested that 80% of the risk of obesity
is conveyed by genetic factors [48]. Some individuals are
more predisposed than others to obesity-associated
diseases, but it is presently difficult to identify the ‘at
risk’ individuals who would benefit the most from indi-
vidualized monitoring and care [49].
In the 1960s, Neel proposed the ‘thrifty gene’ hypothesis
[50], whereby genes that predispose to obesity would have
had a selective advantage in populations that frequently
experienced starvation.
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(ksr2), an intracellular scaffolding protein involved in
multiple signaling pathways [49]. Targeted deletion of
ksr2 leads to obesity in mice, suggesting a role in energy
homeostasis as highly efficient in conserving energy. The
expression of genes mediating oxidative phosphorylation
is also downregulated in the adipose tissue of ksr2(−/−)
mice [49]. This ‘hunger gene’ (ksr2) may cause continued
hunger pangs in patients who are obese, as well as slow
their metabolism. People who possess these genes in today’s
obesogenic environment might be not just slightly over-
weight but becoming extremely obese [49]. These observa-
tions and our in vitro findings suggest that pharmacological
approaches based on the modulation of KSR2 activity could
represent a novel potential therapeutic strategy for the
treatment of obesity and type 2 diabetes.
Rare familiar obesity
Rare familiar obesity include the pure forms of obesity,
where the gene defect is in appetite regulation, and the
disease is characterized by severe early onset obesity
because of hyperphagia; syndromic forms have provided
additional insights into the mechanisms underlying
obesity [51,52]. Thus, cloning of the mouse ob gene and
its human homologue, leptin [51], proved a paradigm of
many genes involved in the regulation of appetite via
the leptin-melanocortin pathway including leptin and
its receptor, the α-melanocortin-stimulating hormone
receptor (MC4R), pro-opiomelanocortin (POMC) and
prohormone convertase-1 [52].
Polygenic obesity
The human obesity gene map [52,53] accumulated in
the field of common polygenic obesity, 253 quantitative
trait loci (QTLs) identified in 61 genome-wide scans
and 52 genomic regions. There are currently 22 gene as-
sociations supported by positive studies [52-54]. These
genes include members of the leptin-melanocortin
pathway, pro-inflammatory cytokines and uncoupling
proteins. The largest numbers of studies have been car-
ried out on ADRB2 and PPARG, but the fact that they
also have reported associations with asthma and T2D,
respectively, may account for this [52]. The TCF7L2
association with diabetes demonstrate that sufficiently
powerful studies can generate statistically strong results
(p < 10−8) [54].
In both rare and common forms of obesity, that
epigenetic influences, defined as any heritable influence
on genes that occurs without a change in the DNA se-
quence, are also important, as the rare Prader-Willi
and Angelman syndromes due to variations in genomic
imprinting at the proximal long arm of chromosome
15 [52,55], gender-related differential responses related
to obesity development [10].Panel of biomarkers for assessing obesity and
associated disorders
It is promising to develop biomarkers, fed through dif-
ferent techniques, applicable to minimize the incidence
of obesity and related disorders, and the morbidity and
mortality it causes, leading to improve prevention and
clinical management strategies. If well-characterized
biomarkers were available, therapeutic intervention to
prevent or delay the onset of obesity or its complica-
tions in susceptible individuals might become possible
[56]. In addition, biomarkers might help us separate
different sub-types of obesity, including those most as-
sociated with diabetes, cardiovascular disease and cancer.
Some are prospective biomarkers for these different states
of health and disease [57-60].
Oxidative stress and obesity
Oxidative stress (OS) has been postulated as one of the
main physiopathological hallmarks of most of chronic
diseases, primarily neurodegenerative diseases, such as
Alzheimer’s disease and other dementias, Parkinson’s
disease, amyotrophic lateral sclerosis, epilepsy and multiple
sclerosis [61,62], arthritis, cardiac dysfunctions and dis-
eases that cause irreversible blindness, diabetic retinop-
athy, macular and retinal degeneration. Lastly, aging of
any body is also associated with oxidative stress because
the activity of the natural antioxidant system declines
with age and the concentration of lipid peroxidation
products increases.
Keaney and colleagues [63] report that smoking, diabetes
and obesity are independently associated with increased
oxidative stress in men and women in a large community-
based cohort. Thus, the pro-inflammatory and pro-oxidant
effects of increased adiposity represent a potential link
between obesity and cardiovascular diseases.
There was an expressed idea that obesity is a state of
chronic oxidative stress and inflammation. Oxidative
stress induced by reactive oxygen species (ROS) is one
of the main factors in cellular aging and many cellular
disorders, which cause extensive damage to DNA [64];
also in mitochondria, it is an interesting promoting factor
in virus-initiated carcinogenesis, metabolism and in-
flammation. In inflammation, ROS and nitric oxide
(NO), generated by inflammatory cells, play a key role
in carcinogenesis. Thus, ROS can induce the formation
of 8-oxodG, an indicator of oxidative DNA damage, and
NO, the formation of 8-nitroguanine, a marker of nitrative
DNA damage. These factors are potentially mutagenic
which may account for the cancer-promoting effect of
inflammation. While therapeutic treatments cannot be
based exclusively on the abatement of oxidative stress,
neutralizing this cellular disorder could minimize col-
lateral damages associated with the transformation of
biomolecules in the cytosol.
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Excess intra-abdominal adiposity has the potential to influ-
ence metabolism and cardiometabolic risk directly through
alterations in the secretion of adipokines. Abdominal obes-
ity promotes increased secretion of a range of metabolites
and of biologically active substances, including glycerol,
FFA, inflammatory mediators (e.g. tumor necrosis factor
alpha (TNFα) and interleukin-6 (IL-6)), plasminogen activa-
tor inhibitor-1 (PAI-1) and C-reactive protein [65-67].
Cardiovascular diseases
Obesity is well known to increase the risk of develop-
ment of cardiovascular diseases. The evidence suggested
an increase in the risk of ischemic heart disease associ-
ated with elevated plasma FFA (top vs lowest tertile)
after correction for non-lipid risk factors, although further
multivariate adjustment for lipid parameters and insulin
weakened the association [67]. The majority of circulating
FFA originates from upper-body subcutaneous adipocytes,
whereas intra-abdominal fat content has been positively
correlated with splanchnic FFA levels which may contribute
to the liver fat accumulation commonly found in abdominal
obesity [68,69].
Adiponectin has been shown to have many favorable
metabolic properties [31-37]. The low adiponectin levels
have been associated with adverse cardiovascular outcomes
[65]. The secretion of adiponectin, an apparently cardiopro-
tective adipokine, has been shown to be reduced in abdom-
inally obese patients [68]. Leptin is an adipokine involved in
the regulation of satiety and energy intake [38,39,65-69];
levels of leptin in the plasma increase during the develop-
ment of obesity and decline during weight loss.
Cardiovascular diseases are strongly connected to im-
mune response. Pathogenesis of cardiovascular diseases is
associated with dysfunction of cytokine production. In most
autoimmune diseases observed, stereotyped response in the
form of a large subpopulation of activated Th1 lymphocytes
[70], not rarely observed, decrease in the number of T
lymphocytes, impaired T helpers/suppressors ratio down-
ward suppressor activity, weakening the response to the
mitogens. In patients with autoimmune disease, frequent
increased levels of pro-inflammatory cytokines (TNF-α,
IL-1, IFN-γ) may result in aberrant activation of the innate
immune response [71]. During a persistent heart muscle
damage, the exposure of the intracellular content to dead
cells activates the innate immune response, such as the
activation of Toll-like receptors (TLR). In the heart, TLR2
and TLR4 are perhaps involved in the host response to
myocardial infarction [72]. The activation of TLR initiates
the imbalance of TLR-induced cytokines regulation [73].
Atherogenesis
Atherosclerosis is a chronic inflammation in the blood
vessels, resulting in the buildup of fatty streaks, and withtime, atherosclerotic plaques. Obesity, insulin resistance
and high blood pressure are the risk factors for the dis-
ease. The gut microbiota has been suggested to play a sig-
nificant role through its processing of phosphatidylcholine
in the diet, leading to pro-atherogenic metabolites in [74].
Atherosclerosis has been shown to have an inflammatory
component, and pro-inflammatory adipokines may be im-
portant mediators of atherogenesis in abdominally obese
subjects [65]. The anti-atherogenic actions of adiponectin
appears to be multifactorial, including inhibition of endo-
thelial activation, reduced conversion of macrophages to
foam cells and inhibition of the smooth muscle prolifera-
tion and arterial remodelling that characterizes the devel-
opment of the mature atherosclerotic plaque [75].
Diabetes, insulin resistance
Steppan et al. described links between obesity and diabetes
by hormone named resistin (for resistance to insulin), a
unique signaling molecule, adipocytes secrete [76]. It was
demonstrated the improvement of lipid metabolism in the
case of probiotic consumption [77]. For example, the
modulation of gut microbiota, e.g. dietary intervention with
oligofructoses, reduced metabolic endotoxemia and
the cecal content of LPS, improved glucose intolerance, in-
sulin sensitivity and decreased body weight gain in both
high-fat fed and ob/ob mice [78].
In models of diabetes, probiotic intervention has been
examined for its ability to impact on metabolic biomarkers
of disease. Tabuchi et al. showed that Lactobacillus
rhamnosus GG improved glucose tolerance in the
streptozotocin-induced rat model of diabetes possibly due
to the prevention of insulin secretion decrease [79]. Studies
using the traditional Indian yoghurt, dahi, supplemented
with probiotic strains of Lactobacillus acidophilus and
L. casei have shown that this product can improve markers
of diabetes, including hyperglycemia, and hyperinsulinemia
in high-fructose-induced rat models of diabetes [80,81].
For instance, it improves insulin sensitivity and glycemic
control [82], and levels of this adipokine correlate positively
with levels of HDL cholesterol and inversely with TG
or PAI-1 [83].
Type 1 diabetes (T1D) is considered as a debilitating
autoimmune disease that results from T cell-mediated
destruction of insulin-producing beta cells. The innate im-
mune system is another factor that probably influences the
composition of the intestinal microbiota. This is best illus-
trated by a study showing that diabetic mice deficient in the
innate signaling molecule MyD88 are protected from the
development of type 1 diabetes [65,84].
Inflammation
Inflammation is a key feature of obesity and type 2 diabetes
[85], being a source of oxidative stress, which is also impli-
cated in the development of atherosclerosis. Elevated levels
Savcheniuk et al. The EPMA Journal 2014, 5:2 Page 9 of 17
http://www.epmajournal.com/content/5/1/2of plasma and urinary F2-isoprostanes have been found
in a number of inflammatory diseases [65,86]; increased
production of reactive oxygen species may also enhance
the inflammatory response by activating redox-sensitive
nuclear transcription factors such as AP-1 and NF-κB.
These transcription factors are essential for the inducible
expression of genes associated with immune and inflamma-
tory responses, including cytokines, cell adhesion molecules
and inducible NO synthase. Thus, the pro-inflammatory
and pro-oxidant effects of increased adiposity represent a
potential link between obesity and CVD. F2-isoprostanes
are prostaglandin-like products of the free radical-catalyzed
peroxidation of arachidonic acid. They are formed in situ
esterified to phospholipids and are released into plasma by
phospholipases [87].
The non-steroidal anti-inflammatory drugs as diclofenac
are associated with the formation of reactive metabolites
and hepatotoxicity [88]; the potential risks of non-steroidal
anti-inflammatory drug for obesity development is promis-
ing but not yet studied.
Atopic diseases and obesity
Most of the studies point out that obesity is capable of in-
creasing the prevalence and incidence of asthma, although
this effect appears to be modest. The treatment of obese
asthmatics must include a weight control program [89].
Obesity is capable of reducing pulmonary compliance,
lung volumes, and the diameter of peripheral respiratory
airways as well as affecting the volume of blood in the
lungs and the ventilation-perfusion relationship. Further-
more, the increase in the normal functioning of adipose tis-
sue in obese subjects leads to a systemic pro-inflammatory
state, which causes a rise in the serum concentrations of
several cytokines, the soluble fractions of their receptors
and chemokines. Many of these mediators are synthesized
and secreted by cells from adipose tissue and receive the
generic name of adipokines, including IL-6, IL-10, eotaxin,
tumor necrosis factor-alpha, transforming growth factors-
beta1, C-reactive protein, leptin and adiponectin.
According to the hygiene hypothesis, it asserts that the
increase in the prevalence of atopic disease is related to
reduced exposure to microbes at an early life [40-42].
According to the study by Shinkai et al. [90], type-2
immunity requires orchestration of innate and adaptive
immune responses to protect mucosal sites from pathogens.
Dysregulated type-2 responses result in allergy or asthma.
T helper 2 (T(H)2) cells elaborate cytokines, such as IL-4,
IL-5, IL-9 and IL-13, which work with toxic mediators of
innate immune cells to establish environments that are
inhospitable to helminth or arthropod invaders.
The importance of T(H)2 cells in coordinating innate
immune cells at sites of inflammation is not known.
Here, we show that polarized type-2 immune responses
are initiated independently of adaptive immunity. In theabsence of B and T cells, IL-4-expressing eosinophils were
recruited to tissues of mice infected with the helminth
Nippostrongylus brasiliensis, but eosinophils failed to
degranulate. Reconstitution with CD4 T cells promoted
accumulation of degranulated IL-4-expressing cells, but only
if T cells were stimulated with cognate antigen. Degranula-
tion correlated with tissue destruction, which was attenuated
if eosinophils were depleted. Helper T cells confer antigen
specificity on eosinophil cytotoxicity, but not cytokine re-
sponses, so defining a novel mechanism that focuses tissue
injury at sites of immune challenge [40,73,89-91].
The cytokine interleukin-17 (IL-17) has received
considerable attention since the discovery of a distinct
CD4(+) T helper (T(H)) cell subset that produces it,
known as the T(H)17 cell subset. Despite the fact that
most of the recent literature describes IL-17 as a T cell-
secreted cytokine, much of the IL-17 released during an in-
flammatory response is produced by innate immune cells.
In this review, we explore the many innate immune cell
populations that are an early source of IL-17 in response
to stress, injury or pathogens. These early sources have
been shown to have a central role in the initiation of
IL-17-dependent immune responses, even before the
first CD4(+)T cell sees its cognate antigen and initiates
the T(H)17 cell developmental program [90,91].
Both systemic and myeloid tissue-specific A(2B) R
deletion significantly decreased pulmonary inflamma-
tory cell recruitment, airway mucin production and
pro-inflammatory cytokine secretion after final allergen
challenge in sensitized mice. A(2B) R deficiency resulted
in a dramatic reduction on Th2-type airway responses
with decreased pulmonary eosinophilia without augment-
ing neutrophilia and decreased lung IL-4, IL-5 and IL-13
production. Pro-inflammatory TNF-α, IFN-γ and IL-17
secretion were also reduced in systemic and myeloid
tissue-specific A(2B) R deletion mouse lines [92]. This
Th2-type dysfunction in bronchial asthma inclines to use
immunocorrection that can be achieved with probiotics
based on Gram-positive microorganisms [93,94].
Infection-related metabolic conditions
It was speculated that adenovirus 36 (Adv36) not only
infects humans but also can make them obese [95]; studies
in humans and experiments in animals supported this
hypothesis. There were illustrated extensive interrelations
among virus action, cellular oxidative stress, gene damage,
multiple immune pathways and proteomic changes in
diabetes mellitus, cancer and many chronic disorders
development; many of them are also related to HPV infec-
tion [96,97]. On the other hand, the obesity may induce
the T cell response in virus infection [98]. Patients with
increased BMI and adiposity also present a higher inci-
dence of surgical site infections with increased risk of
wound complications [85,99].
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Findings showing women’s differential metabolic re-
sponses have suggested a gender effect on biochemical-
endocrinological patterns, metabolic mechanisms and
risk factors, emphasizing the importance of more gender-
specific prevention strategies [10]. This is especially relevant
vs environmental changes and the obesogenic epidemic,
with women’s lead in earlier and higher obesity rates
and related disease risk, though with manifestation mostly
delayed to menopausal age. Estrogen receptors (ER) are
well-known regulators of several aspects of metabolism,
including glucose and lipid metabolism, and impaired
estrogen signaling is associated with the development
of metabolic diseases [10,100]. Here, ERα seems to play
a protective role in insulin and glucose metabolism
through effects on the liver, adipose tissue, muscle, and
pancreatic β cells and on central regulation of food in-
take and energy expenditures. ERβ, on the other hand,
has the potential to negatively influence insulin and glu-
cose metabolism by impairment of adipose tissue func-
tion. The onset of menopause dramatically increases the
risk for women to develop disease states coupled to the
metabolic syndrome, such as obesity, CVD, and type 2
diabetes [10]. The endometrial receptor status being
strongly associated with metabolic mechanisms contrib-
ute the diagnostic algorithm as potential biomarkers
for pathogenetic therapy. Thus, in determining rela-
tionships in the endometrial receptor system, each in-
dividual pathological pattern of receptors and their
relationship further defines personalized pathogenetic
tactics tailored to the person [100].
Hyperuricemia, gout
Hyperuricemia, which is strongly associated with obesity
and metabolic syndrome and can predict visceral obesity
and insulin resistance, might be partially responsible for
the pro-inflammatory endocrine imbalance in the adipose
tissue, which is an underlying mechanism of the low-
grade inflammation and insulin resistance in subjects with
the metabolic syndrome [101] and is discussed to be in-
volved in the mechanism of MSG metabolism. Gutman in
1973 [102] expressed the hypothesis that, possibly second-
ary to altered glutamate catabolism, glutamine apparently
is overutilized for urate overproduction by the liver and
underutilized for reduced renal ammonia formation. The
kidneys, modulating urinary uric acid excretion, sustain
the hyperuricemia. In these considerations of the possible
role of glutamine, another factor should now be taken into
account, namely, the hyperglutamatemia of primary gout.
Pagliara and Goodman suggested that in gout, the im-
paired catabolism is due to a partial deficiency of glu-
tamate dehydrogenase; gouty patients had raised levels
of plasma glutamate [103]. Certain foods and food ad-
ditives are used along with monosodium glutamate, orMSG, to enhance the flavor of bland food, and contain
purines, which are directly metabolized into uric acid,
as guanylate (E626, E627, E628 and E629), inosinate
(E630, E631, E632 and E633), and their compounds
ribonucltides (E634 and E635) are metabolized to purines.
More studies are required to establish the links with food
additives and crystal deposition diseases, prior to gout.
Gout is characterized by the deposition of reversible
monosodium urate (MSU) crystals and occurs as a con-
sequence of hyperuricemia [104] which induces inflam-
matory arthritis [105] and nephropathy [106] and has
risen over the last decade. Dr. Veronique Vitart, from
the Medical Research Council Human Genetics Unit at the
University of Edinburgh, researcher of hyperuricemia gen-
etics said: ‘Abnormal levels of uric acid have been associated
with various common diseases and conditions, but causal
relationships are not always clear. Gaining insight into the
genetic components of uric acid levels offers a very useful
tool to tackle these issues and to further our understanding
of these conditions.’ In the study by Köttgen et al., including
110,347 individuals from 48 studies were suggested and
28 genome-wide significant loci associated with serum
urate concentrations were identified. Those alleles asso-
ciated with increased serum urate concentrations were
also associated with increased risk of gout. The modulation
of urate production and excretion by signaling processes
that influence metabolic pathways, such as glycolysis and
the pentose phosphate pathway, seems to be central path-
ways including the genes from the newly identified associ-
ated loci. These findings may have implications for further
research into urate concentration, lowering drugs to treat
and prevent the common inflammatory arthritis gout [107].
Advanced imaging modalities including MRI, ultrasound
(US), CT and dual energy CT have important applications
in gout. US and MRI also reveal the severity of inflam-
mation within and adjacent to the joint and can cap-
ture information about the composite, vascular nature
of many tophaceous deposits [104,108]. According to
our recent data [109], ultrasound can be an effective
method for early detection of liver and kidney involvement
in gout patients with sensitivity, specificity, positive and
negative predictive value and accuracy; the gout involve-
ment of liver and kidneys using complex ultrasonography
diagnostic criteria were 92.6%, 84.4%, 80%, 95% and 91.9%
respectively. We suggested the integrated index calculated
by suggested mathematical model according to which the
process (disease progression) is described by the primary
indicators (biomarkers) that with output rate are stochastic
in nature and presented as statistical information. A special
algorithm for processing statistical data could be reliable for
disease staging and control treatment follow up. We
recommended to create the system for complex evaluation
of biomarkers using suggested mathematical model based
from patient medical records for prediction, personalized
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ism and obesity that may be applicable in still existing
closed medical system, obtaining relevant extensive data.
Immune pathways
The ability of probiotics, which affects the relevant Toll-like
receptors (TLRs), can promote effective immune response
and the initiation of an effective immune defense [73].
Gram-positive bacteria affect the formation of T and B cell
immune response by altering products primarily; IFN-γ
and IL-12 are required for differentiation of T helper cells
into Th1 subpopulation direction. However, probiotic
preparations are capable of activating both (Th1 and Th2)
lymphocyte subpopulations, which provide a balance of
cytokine production. Immunomodulatory activity of pro-
biotic preparations is most important to identify the goods
which induced opposite cytokines IL-10 or IL-12 in exper-
iments in vitro when stimulating macrophage cells. The
immune response against infectious diseases of probiotic
drugs is activated due to the ability to balance the body’s
immune status at the level of receptor-ligand interactions.
Probiotic preparations are the agonists TLR-2, and the
presence of common protein adapter molecules (TIRAP),
MyD88 for TLR-2 and TLR-4 to influence the signaling
pathways of cytokine production under the influence of
the ligands. Inhibition of TLR2-induced signaling, influ-
enced by lactobacilli via adapter Mal/MyD88, can lead
to partial inhibition of TLR4 signal, accompanied by de-
creased production of pro-inflammatory cytokines. Ability
to influence signaling pathways of cytokine production
opens new perspectives for the creation of probiotic prep-
arations with anti-inflammatory properties.
According to our recent data [110], daily oral admin-
istration of strains L. rhamnosus V® or L. rhamnosus
LB3 IMB B-7038 (1 × 106 cells / mouse) for 4 days and
infected Staphyloccous aureus 8325 mice in a dose
(5 × 108 CFU/mouse) LD50 was accompanied by a reduc-
tion in the mortality of animals. The introduction of lactic
acid bacteria to the animals infected with S. aureus allowed
increased functional activity of phagocytic system and
the normalization parameters of cellular immunity ac-
tivation and production of interferon-γ and IL-12 in
different periods of observation. However, decreased
production of IL-4 indicates the ability of probiotic strains
to balance the immune response in the upward cytokine
production by Th1-type, which guide the development
of the immune response to cell type. The introduction
of lactic acid bacteria accompanied the strengthening of
the ability of splenocytes to produce IFN-α and IFN-γ
in response to adequate stimulation. Strengthening
biocide activity of macrophages and cytotoxicity natural
killer under the influence of experimental strains leads
to a significant increase of elimination S. aureus-infected
kidneys of animals.These data suggest that lactic acid bacteria may
dynamically modulate the mechanisms of innate and
adaptive immunity by maintaining the balance between
Th1 and Th2 lymphocytes, which allows us to consider
them as immunomodulatory drug selective action [108].
Associations with neurodegenerative, musculoskeletal
diseases and pain
Interferon-b is an established treatment for patients with
multiple sclerosis (MS), but its mechanisms of action are
not well understood [111]. Viral infections are a known
trigger of MS relapses. Toll-like receptors (TLRs) are key
components of the innate immune system, which sense
conserved structures of viruses and other pathogens
[73]. The upregulation of TLR7 in pDCs and a conse-
quently increased activation of pDCs by TLR7 ligands
represents a novel immunoregulatory mechanism of
interferon-b. Derkow et al. hypothesized that this mechan-
ism could contribute to a reduction of virus-triggered re-
lapses in patients with MS [111].
Many studies clearly suggest that TLRs, acting through
MyD88-dependent and/or independent mechanisms,
induce pro-inflammatory signals for the development
of myopathy in skeletal muscles. Thus, the emerging
paradigm indicates that not only innate and adaptive
immune mechanisms but also intrinsic defects in myo-
pathic skeletal muscle contribute to muscle weakness and
damage such as myositis. The muscle microenvironment
is complex, consisting of active interactions occur between
innate, adaptive, metabolic and homeostatic pathways in
the muscle in these diseases [112].
Acute exposure of skeletal muscle to elevated levels
of FFA induces insulin resistance, whereas chronic ex-
posure of the pancreas to elevated FFA impairs β-cell
function [113,114]. Obesity-related postural mechanism,
neuromuscular networks and pain muscle and immune-
neurodegenerative relationships are still unclear and sub-
ject for further studies [115].
Vasospasm, congestion and obesity
Endothelial dysfunction (ED) induced by obesity is an
important risk factor that impairs blood flow controls in
various organs. Obesity impairs microvascular function in
several ways. ED results from an imbalance between NO
and endothelin (EDN), being the regulators of vascular
function. Obesity-induced ED is associated with decreased
NO production due to impaired endothelial NO synthase
activity and expression and increased production of super-
oxide anion and the endogenous NOS inhibitor ADMA,
together with increased vasoconstrictor factors, such as
endothelin-1 and sympathetic nerve activation [116].
Genetic variants in NO synthase and EDN isoforms
and its receptors (EDNRA and EDNRB) appear to ac-
count for important components of the variance in ED,
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ity exist. Analysis of genotype-phenotype interactions
is critical for the formulation of the potentially altering
predisposition to cardiovascular diseases [117]. NO
synthase and endothelin genes are related with many
diseases, namely, asthma [118] and renal failure [119],
that make them the potential biomarkers of numeral
obesity collateral pathologies.
Meyer et al. found that in the aorta of obese mice,
perivascular adipose potentiates vascular contractility
to serotonin and phenylephrine, indicating the activity
of a factor generated by perivascular adipose, which we
designated as ‘adipose-derived contracting factor’ (ADCF)
[120]. Inhibition of cyclooxygenase (COX) fully prevented
the ADCF-mediated contractions, whereas COX-1 or
COX-2-selective inhibition was only partially effective.
By contrast, inhibition of superoxide anions, NO syn-
thase, or endothelin receptors had no effect on ADCF
activity [120].
Congestive mesenteric [121] and/or pelvic syndromes
(ovarian vein reflux) [122] are the condition characterized
by the presence of venous congestion and varicose veins
in the mesenteric and pelvic region and play important
role for dysregulation of intestinal and systemic micro-
circulation mechanisms leading to ED in overweight pa-
tients and have potential risk for the development of
many vascular and hormonal disorders related to obesity.
In obese individuals, the mixed meal drink decreases the
baseline skin perfusion and causes acetylcholine-mediated
vasodilation but has no effect on the capillary density.
Obese individuals had impaired acetylcholine-mediated
vasodilation after meal ingestion. The latter findings are
consistent with impaired postprandial microvascular func-
tion in obesity [123].
Peripheral microcirculation assessment might be con-
sidered to support a supplementary information for
obese patients particularly for vasospasm assessment
[124], including laboratory biomarkers and capillaroscopy
[125]; Doppler techniques for assessment of vascular re-
sponses following cuff-induced arterial occlusion allow
determinations of the kinetics of post-ischemic reperfu-
sion and provides an accurate reporter of NO-mediated
physiological recruitment [117].
Nanotechnologies - the challenge for advanced diagnosis,
treatment and prevention
Advances in nanoscience, nanotechnology and nanomedi-
cine lead to the construction of new materials and devices
for various scientific and therapeutic purposes which
are applicable in molecular diagnostics, nanodiagnostics
and improvements in the discovery, design and delivery
of drugs, including nanopharmaceuticals. The applica-
tion of nanoparticles allowing the combination of ther-
apy and diagnosis, known as theranostic, has receivedincreasing attention in biomedicine [126]. Pharmaco-
logical, pharmaceutical and toxicological aspects of the
application of nanoparticles in biomedical purposes still
remain poorly understood. While oxidative stress has
been postulated as one of the main physiopathological
hallmarks of most of chronic diseases, the nanoparticles
of gold [126,127] and cerium dioxide [118,119] were re-
ported as strong agents against oxidative damage hav-
ing anti-aging activity. Nanoparticles of cerium dioxide,
considering its UV-shielding effect, antiviral, antibacterial,
antifungal activity, cardioprotective, neurotrophic, hepato-
and nephroprotective and anti-aging effect, have potential
for various biomedical applications [126-129]. Treatment
with nanoceria has supplementary perspectives in gyne-
cology and reproductive medicine and also in women with
hormone-associated obesity which results from the increase
in the number of oocytes in follicles, increase in the num-
ber of oocytes at metaphase I and metaphase II, increase in
the number of living granulosa cells and decrease in the
number of necrotic and apoptotic cells [128,129].
Potential economical impacts
Obesity as a condition associated to many pathologies ac-
counts for the burden related to the treatment of these pre-
ventable diseases (about €59 billion a year in EU; US$71.1
billion in the USA). The combined medical costs attrib-
utable to obesity and overweight are projected to double
every decade and will account for 16% to 18% of the
total US health care expenditure by 2030 [130]. Thus,
considering integrative medical approach against obes-
ity within the PPPM paradigm should lead to significant
economic benefits.
Education for preventive measures
Educational programs and individual preventive facilities
are the important tasks for the PPPM concept in metabolic
disorder early risk factors detection and early obesity
environment programming. A number of potential effect-
ive plans can be implemented to target built environment,
physical activity and diet. Primary or secondary prevention
of obesity and these strategies are more effective in
children than in adults [131]. These strategies can be
initiated at home and in preschool institutions, schools or
after-school care services as natural setting for influencing
the diet and physical activity and at home and work for
adults. Dissemination of information is necessary in or-
der to popularize dietary recommendations, screening
programs and patient participation approaches against
risk factors including obesity, fat diet, diabetes, women
health and family history. The material for dissemin-
ation and lecturing should be culture specific and eth-
nically standardized to the socio-economical aspects of
the targeting population (well translated, to be easily
understood) in order to facilitate the work. Development
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supported questionnaires are required to assessment
conditions specific to obesity which is tailored to the
person. Support of preventive educational activity with
long-term commitment of private and public funding
programs is required.
Consolidation of the PPPM concept
Personalized medical approach
Avoiding adverse additive and designing person-related
probiotic strains are important impacts to personal-
ized dietology.
Predictive medical approach
Translating obtained data on animal model to human
organism may allow to consider consumption of the
products containing MSG, especially in early age, as a
predictive value for obesity and metabolic syndrome
development. Developing the panel of obesity assess-
ment biomarkers is an important point.
Preventive medical approach
Translation of the obtained data on animal model to human
organism may allow to consider diet correction with pro-
biotics within early obesity environment programming as
a strong preventive measure against obesity epidemic.
Expert recommendations
Conclusion
The introduction of monosodium glutamate to newborn
rats causes obesity in adulthood. Periodic administration
of probiotic blends to rats that received MSG in neo-
natal period prevented the development of obesity.
Future outlooks and recommendations
Further studies including sufficient cohorts of volunteers
are necessary to translate model data of probiotic efficacy
to human population as well as conduction of epidemio-
logical studies for obtaining evidence regarding adverse
effect of particular food additives.
We also suggest the further studies regarding obesity
and metabolic disorders inducible by expression of genes
associated with obesity environment, dietary additives,
immune and inflammatory responses, and develop and test
promising nanomaterials (e.g. nanoceria) for prospect of
complex impact to gastrointestinal microbiota and motility.
Create the relevant models to study microbiota related to
specific process (diabetes, gout, hepatitis, cancer, CVD, etc.).
Obtained results may indicate the effectiveness of probiotic
therapy to prevent obesity in human based on personalized
microbiota additives. To achieve the personalized ap-
proach, the development and application products man-
ufactured from own strains of organism are considered
promising. The potential alternative for probiotics might bethe suggested lysates of probiotic strains that also exhibit
immunomodulatory activity.
After approval, development of safe and effective person-
related medications/additives with future clinical test-
ing should be initiated to implement results for routine
practice.
With the concluding points, we can formulate the
following proposals (expert recommendations):
1. For the European Union (EU): create an
international project to study the effects of
probiotics for the implementation of evidence-based
personalized dietology against obesity and metabolic
syndrome.
2. For Ukraine: participate in the project in partnership
with EU to follow up experimental and clinical
trials and involve related institutions and centres
to the study.
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